13F Pro quality score
Rank #2,247 of 2,819
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Sunshine Biopharma Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $36.3M | $-6.0M | -17.2% |
| FY 2024 | 10-K | $34.9M | $-5.1M | -16.7% |
| FY 2023 | 10-K | $24.1M | $-4.5M | -19.9% |
| FY 2022 | 10-K | $4.3M | $-26.7M | — |
| FY 2021 | 10-K | $228.4K | $-12.4M | — |
| FY 2020 | 10-K | $71.4K | $-2.8M | — |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
1 transaction in SBFM reported by 1 member of Congress under the STOCK Act, most recent trade Jun 30, 2022. Reported transactions, not recommendations.
Sunshine Biopharma Inc. (SBFM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SBFM at 33.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,247 of 2,819 stocks — the bottom half of the AI-ranked universe. SBFM scores in the top quartile across revenue growth (85.8). Areas of concern include revenue scale (8.0) and balance sheet strength (11.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Sunshine Biopharma Inc. reports quarterly revenue of $9.3M, net income of $-1.6M, an operating margin of -17.4%. Top institutional holders of SBFM by reported 13-F value include JANE STREET GROUP, MORGAN STANLEY, UBS Group AG, based on the most recent SEC filings. SBFM trades on the Nasdaq exchange and files with the SEC under CIK 1402328. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SBFM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sunshine Biopharma Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1402328 →